Medicare announces plan to negotiate prices of diabetes, weight loss drugs
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.
Ozempic could get cheaper as Medicare eyes drug price negotiations — and Novo Nordisk stock slips
The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of price negotiations, including the popular weight loss drugs Ozempic and Wegovy.
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Ozempic, Wegovy and Other Drugs Are Among 15 Selected for Medicare's Price Negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Monthly Prescribing Reference3y
Trelegy Ellipta
Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic ...
pharmaphorum6d
COPD triple approved, can GSK maximise its revenues?
Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple ... offer Trelegy at a discount to the sum cost of the individual therapies, rather ...